Ed F. Schnipper
Fundador en Velocity Pharmaceutical Development LLC .
Perfil
Ed F.
Schnipper founded Velocity Pharmaceutical Development LLC in 2011, where he is working as Chief Medical Officer & Managing Director from 2011.
Dr. Schnipper also founded Velocity Pharmaceutical Holdings LLC and Menlo Therapeutics, Inc., where he worked as Director.
Dr. Schnipper also currently works at Spitfire Pharma, Inc., as President, American Society of Clinical Oncology, Inc., as Member, and American Academy of Pharmaceutical Physicians, as Member.
Dr. Schnipper also formerly worked at Cellgate, Inc., as President & Chief Executive Officer from 2001 to 2007, SEQUUS Pharmaceuticals, Inc., as Medical Director & Senior Vice President, Neos Therapeutics, Inc., as Director, ALZA Corp., as Vice President-Clinical Development from 1997 to 2001, DNIB Unwind, Inc., as Chief Medical Officer, DNIB Unwind, Inc., as Chief Medical Officer in 2014, Hoffmann-La Roche, Inc., as Vice President-Clinical Operations from 1983 to 1996, and Novacea, Inc., as Chief Medical Officer & Executive Vice President from 2007 to 2008.
Dr. Schnipper received his undergraduate degree from Hobart & William Smith Colleges and doctorate degree from Georgetown University School of Medicine.
Cargos activos de Ed F. Schnipper
| Empresas | Cargo | Inicio |
|---|---|---|
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Corporate Officer/Principal | - |
| American Academy of Pharmaceutical Physicians | Corporate Officer/Principal | - |
Velocity Pharmaceutical Development LLC
 Velocity Pharmaceutical Development LLC Drugstore ChainsRetail Trade Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA. | Fundador | 01/01/2011 |
Spitfire Pharma, Inc.
 Spitfire Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Spitfire Pharma, Inc. provides drug development and research services. The firm’s products include SP-1373, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis. The company was founded by John J. Nestor, Jr. and is headquartered in South San Francisco, CA. | Presidente | - |
Antiguos cargos conocidos de Ed F. Schnipper.
| Empresas | Cargo | Fin |
|---|---|---|
| DNIB UNWIND INC | Director Técnico/Científico/I+D | 07/11/2014 |
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Director Técnico/Científico/I+D | 01/10/2008 |
Cellgate, Inc.
 Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | Director Ejecutivo | 01/11/2007 |
| ALZA CORPORATION | Corporate Officer/Principal | 01/09/2001 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 01/01/1996 |
Formación de Ed F. Schnipper.
| Hobart & William Smith Colleges | Undergraduate Degree |
| Georgetown University School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 13 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
SEQUUS Pharmaceuticals, Inc.
 SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Health Technology |
DNIB Unwind, Inc.
 DNIB Unwind, Inc. BiotechnologyHealth Technology DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA. | Health Technology |
Menlo Therapeutics, Inc.
 Menlo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA. | Health Technology |
Spitfire Pharma, Inc.
Spitfire Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Spitfire Pharma, Inc. provides drug development and research services. The firm’s products include SP-1373, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis. The company was founded by John J. Nestor, Jr. and is headquartered in South San Francisco, CA. | Commercial Services |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Cellgate, Inc.
Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | Health Technology |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
| American Academy of Pharmaceutical Physicians | |
Velocity Pharmaceutical Holdings LLC
 Velocity Pharmaceutical Holdings LLC Financial ConglomeratesFinance Velocity Pharmaceutical Holdings LLC operates as a holding American company. | Finance |
Velocity Pharmaceutical Development LLC
Velocity Pharmaceutical Development LLC Drugstore ChainsRetail Trade Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA. | Retail Trade |
- Bolsa de valores
- Insiders
- Ed F. Schnipper
